GR3025485T3 - Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones - Google Patents

Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Info

Publication number
GR3025485T3
GR3025485T3 GR970403134T GR970403134T GR3025485T3 GR 3025485 T3 GR3025485 T3 GR 3025485T3 GR 970403134 T GR970403134 T GR 970403134T GR 970403134 T GR970403134 T GR 970403134T GR 3025485 T3 GR3025485 T3 GR 3025485T3
Authority
GR
Greece
Prior art keywords
ones
antiatherosclerotic
benzoxazine
benzopyran
antithrombotic
Prior art date
Application number
GR970403134T
Other languages
English (en)
Inventor
Ronald B Gammill
Thomas M Judge
Joel Morris
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GR3025485T3 publication Critical patent/GR3025485T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR970403134T 1990-06-20 1997-11-26 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones GR3025485T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54112690A 1990-06-20 1990-06-20
PCT/US1991/004140 WO1991019707A2 (en) 1990-06-20 1991-06-18 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Publications (1)

Publication Number Publication Date
GR3025485T3 true GR3025485T3 (en) 1998-02-27

Family

ID=24158277

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970403134T GR3025485T3 (en) 1990-06-20 1997-11-26 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Country Status (10)

Country Link
EP (1) EP0525123B1 (el)
JP (1) JPH05509302A (el)
AT (1) ATE158288T1 (el)
AU (1) AU7998291A (el)
CA (1) CA2081577A1 (el)
DE (1) DE69127690T2 (el)
DK (1) DK0525123T3 (el)
ES (1) ES2106783T3 (el)
GR (1) GR3025485T3 (el)
WO (1) WO1991019707A2 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles
US6180625B1 (en) 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
AU3704400A (en) * 1999-03-04 2000-09-21 E.I. Du Pont De Nemours And Company Fused bicyclic oxazinone and thiazinone fungicides
CA2398163C (en) 2000-01-24 2011-02-22 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
PL211300B1 (pl) 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
CN100430389C (zh) * 2002-08-16 2008-11-05 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
JP4646626B2 (ja) * 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド３−キナーゼβの阻害
JP2006523237A (ja) * 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
DK1631295T3 (da) * 2003-06-06 2010-06-21 Arexis Ab Anvendelse af kondenserede heterocykliske forbindelser som SCCE-inhibitorer ved behandling af hudsygdomme
DE602004026071D1 (de) 2003-08-13 2010-04-29 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
BRPI0515498A (pt) 2004-09-20 2008-07-29 Kudos Pharm Ltd inibidores de dna-pk
TW200638938A (en) 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
EP2208728A4 (en) * 2007-09-19 2011-12-21 Inst Med Molecular Design Inc HETEROCYCLIC DERIVATIVE DERIVATIVE DERIVATIVE TO 11 -? - HYDROXYSTEROIDDEHYDROGENASE TYPE I
KR20100118977A (ko) * 2008-01-25 2010-11-08 아스트라제네카 아베 거울상이성질체적으로 순수한 (-) 2-[1-(7-메틸-2-(모르폴린-4-일)-4-옥소-4Ｈ-피리도[1,2-α]피리미딘-9-일)에틸아미노]벤조산, 의학 치료에서의 이의 용도 및 이를 포함하는 약학 조성물-026
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2808322B1 (en) 2012-01-26 2017-08-23 Daiichi Sankyo Company, Limited Chromone derivative having osteogenesis promoting effect
MX2024001829A (es) * 2021-08-12 2024-04-26 Shanghai Simr Biotechnology Co Ltd Derivado de triazol sustituido, metodo de preparacion del mismo, composicion farmaceutica del mismo y uso del mismo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555290A1 (de) * 1975-12-09 1977-06-16 Boehringer Mannheim Gmbh Neue benzopyron-derivate und verfahren zu ihrer herstellung
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
AU634994B2 (en) * 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Also Published As

Publication number Publication date
WO1991019707A2 (en) 1991-12-26
WO1991019707A3 (en) 1992-03-05
ES2106783T3 (es) 1997-11-16
DE69127690D1 (de) 1997-10-23
CA2081577A1 (en) 1991-12-21
DK0525123T3 (da) 1998-05-04
JPH05509302A (ja) 1993-12-22
EP0525123A1 (en) 1993-02-03
DE69127690T2 (de) 1998-02-12
ATE158288T1 (de) 1997-10-15
EP0525123B1 (en) 1997-09-17
AU7998291A (en) 1992-01-07

Similar Documents

Publication Publication Date Title
GR3025485T3 (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
BG101112A (en) The use of heterocyclic compounds
ZA988158B (en) Sulfinic acid derivatives and their preparation and use
DE58906377D1 (en) Difluormethylverbindungen.
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
MX9604367A (es) Hidroxipiridinonas novedosas.
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
EP0235692A3 (en) Oligopeptidyl nitrile derivatives, the agents containing them, process for their preparation and their use
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
NZ237884A (en) N-hydroxy-n-linolanyl (chromanyl or quinolinyl) alkyl urea and amide derivatives, preparation and pharmaceutical compositions thereof
EP0467206A3 (en) Dicarboxylique acid imides, process for their preparation and their use as herbicides
MY103241A (en) Imidazole and 1,2,4 triazole derivatives
TW340115B (en) Triazine derivatives and pharmaceutical composition for hepatitis the invention relates to triazine derivatives and pharmaceutical composition for hepatitis
TW223630B (en) Retroviral protease inhibitors
ZA906531B (en) Substituted n-(quinolin-2-yl-methoxy)benzyl-sulphonyl-ureas
MY132057A (en) Quinoxalinones, a process for their preparation and their use
MY117934A (en) Process for the preparation of n-methyl-3-(1-methyl-4- piperidinyl)-1h-indole-5-ethanesulphonamide
IS4725A (is) Afleiður amidíns og ísóþíóþvagefnis er hindra nítrítoxíðsyntasa
GR79628B (el)
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors
EP0420116A3 (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
NO912420L (no) Antiatherosklerotiske og antitrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoksazin-4-oner.
TW329388B (en) Intraocular irrigating solution